Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval G. Daver, MD, Pau Montesinos, MD PhD, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Nikolaos Papadantonakis, MDPhDMSc, Eric Deconinck, MD PhD, Harry P. Erba, MD PhD, Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, David A. Rizzieri, MD, Kendra L. Sweet, MD, Giovanni Martinelli, Corrado Tarella, MD, Elisabetta Todisco, MD PhD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, PhD, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 734.

https://doi.org/10.1182/blood-2019-128648

Published: 2019

Journal Articles

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval G. Daver, MD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Jiuzhou Wang, PhD, Kara E. Malcolm, RN, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 2601.

https://doi.org/10.1182/blood-2019-128501

Published: 2019

Journal Articles

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Claire N Harrison, Professor, Jacqueline S Garcia, MD, Ruben A Mesa, MD, Tim CP Somervaille, MD PhD, Rami S. Komrokji, MD, Naveen Pemmaraju, MD, Catriona Jamieson, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, James M. Foran, MD, Casey L. O'Connell, MD, Leanne Holes, BS, MBA,, Jia Jia, PhD MBA, Jason Harb, PhD, Jessica Hutti, PhD, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 671.

https://doi.org/10.1182/blood-2019-130158

Published: 2019

Journal Articles

Ramp-up Treatment Strategy in Philadelphia Positive Acute Lymphoblastic Leukemia Is Associated with Deep Molecular Remissions and Favorable Outcomes

Nabiel A. Mir, MD, Charles Bodine, MD, Denise Peker, MD, Kimo Bachiashvili, MD, Pankit Vachhani, MD, Luciano J. Costa, MD PhD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MD PhD MSc

Blood (2019) 134 (Supplement_1): 5120.

https://doi.org/10.1182/blood-2019-128770

Published: 2019

Journal Articles

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Justin M. Watts, MD, Terrence J Bradley, MD, Amber Thomassen, Andrew M. Brunner, MD, Mark D. Minden, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Sameem Abedin, MD, Amanda J Baines, Olena Barbash, PhD, Shelby Gorman, Brandon E Kremer, MD PhD, Gautam M. Borthakur, MD

Blood (2019) 134 (Supplement_1): 2656.

https://doi.org/10.1182/blood-2019-130337

Published: 2019

Journal Articles

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

Naval G. Daver, MD, Harry P. Erba, MDPhD, Nikolaos Papadantonakis, MDPhDMSc, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Marina Y. Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 27.

https://doi.org/10.1182/blood-2018-99-112955

Published: 2018

Journal Articles

Omission of Maintenance in Patients with High-Risk Acute Promyelocytic Leukemia (APL) in the Era of ATRA/Arsenic Consolidation

Gaurav Shah, MD, Fady M. Mikhail, MD PhD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MD PhD MSc

Blood (2018) 132 (Supplement 1): 5192.

https://doi.org/10.1182/blood-2018-99-114872

Published: 2018

Journal Articles

The Impact of Cumulative Dose of Cytarabine Consolidation on Outcomes in Older Patients with Acute Myeloid Leukemia

Laura M Stanko, MD, Luciano J Costa, MD PhD, Denise Peker, MD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MD PhD MSc

Blood (2018) 132 (Supplement 1): 2687.

https://doi.org/10.1182/blood-2018-99-117769

Published: 2018

Journal Articles

Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy

Omer Jamy, MD, Charles Bodine, MD, Rehan Sarmad, MD MBBS, Awal Chadha, MBBS, Pankit Vachhani, MD, Luciano J Costa, MD PhD, Ayman Saad, MD, Nikolaos Papadantonakis, MDPhD MSc, Harry P. Erba, MD PhD, Antonio Di Stasi, MD

Blood (2018) 132 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2018-99-114090

Published: 2018

Journal Articles

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Daniel J. DeAngelo, MD, Harry P. Erba, MDPhD, Elie Traer, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Cecilia Arana-Yi, MD, William Blum, MD, Callum M. Sloss, PhD, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, MD PhD, Eunice S. Wang, MD

Blood (2018) 132 (Supplement 1): 26.

https://doi.org/10.1182/blood-2018-99-112891

Published: 2018

Journal Articles

Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow

Omer Jamy, Sejong Bae, Luciano J. Costa, MD PhD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MD MSc

Blood (2017) 130 (Supplement 1): 3871.

https://doi.org/10.1182/blood.V130.Suppl_1.3871.3871

Published: 2017

Journal Articles

Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response

Caner Saygin, MD, Nikolaos Papadantonakis, MD PhD, Ryan D Cassaday, MD, Michaela Liedtke, MD, Katrina Fischer, MD, Tamara J. Dunn, MD, Bhumika Patel, MD, Sean Hobson, Cassie Zimmerman, Jaime Lynn Fensterl, MS, MBA, Ronald M. Sobecks, MD, Matt Kalaycio, MD FACP, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD, PhD, M.P.H., Aaron T. Gerds, MD MS, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD

Blood (2016) 128 (22): 1603.

https://doi.org/10.1182/blood.V128.22.1603.1603

Published: 2016

Journal Articles

Lysyl oxidase is associated with increased thrombosis and platelet reactivity

Shinobu Matsuura, Rongjuan Mi, Milka Koupenova, Alexia Eliades, Shenia Patterson, Paul Toselli, Jonathan Thon, Joseph E. Italiano, Jr, Philip C. Trackman, Nikolaos Papadantonakis, Katya Ravid

Blood (2016) 127 (11): 1493–1501.

https://doi.org/10.1182/blood-2015-02-629667

Published: 2016

Includes: Supplemental data

Journal Articles

The Role of Post- Treatment Imaging in Detection of Relapsed Disease in Classical Hodgkin Lymphoma: The Cleveland Clinic Experience

Nikolaos Papadantonakis, MD PhD, Basel Rouphail, MD MBA, Jia Xuefei, Robert M. Dean, MD, Brian T. Hill, MD PhD, Brad Pohlman, MD, Mitchell R. Smith, MD PhD, Deepa Jagadeesh, MD MPH

Blood (2015) 126 (23): 5006.

https://doi.org/10.1182/blood.V126.23.5006.5006

Published: 2015

Journal Articles

CD14 and Tissue Factor Positive Extracellular Vesicles Predict Response to Dovitinib in Patients with GBM: A Pilot Study

Nikolaos Papadantonakis, MD PhD, Manmeet S Ahluwalia, MD, Micheal Khoury, MD, Shruti Chaturvedi, MD, Keith R. McCrae, MD

Blood (2014) 124 (21): 4999.

https://doi.org/10.1182/blood.V124.21.4999.4999

Published: 2014

Journal Articles

Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib

Ahmad Zarzour, MD, Ali Tabarroki, MD, Valeria Visconte, PhD, Rokana Taftaf, MD, Heesun J. Rogers, MD PhD, Jing Ai, MD PhD, Nikolaos Papadantonakis, MD PhD, Alan E. Lichtin, Yogen Saunthararajah, MD, Brady L Stein, MDMHS, Ramon V. Tiu, MD

Blood (2014) 124 (21): 1834.

https://doi.org/10.1182/blood.V124.21.1834.1834

Published: 2014

Journal Articles

Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib

Ahmad Zarzour, MD, Ali Tabarroki, MD, Rokana Taftaf, MD, Valeria Visconte, PhD, Jing Ai, MD PhD, Betty K. Hamilton, MD, Nikolaos Papadantonakis, MD PhD, Alan E. Lichtin, Leonard J. Horwitz, MD, Anjali S. Advani, MD, Mikkael A. Sekeres, MD MS, Ramon V. Tiu, MD

Blood (2014) 124 (21): 1835.

https://doi.org/10.1182/blood.V124.21.1835.1835

Published: 2014

Journal Articles

Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection

Nikolaos Papadantonakis, Shinobu Matsuura, Katya Ravid

Blood (2012) 120 (9): 1774–1781.

https://doi.org/10.1182/blood-2012-02-402594

Published: 2012

NARROW

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Ramp-up Treatment Strategy in Philadelphia Positive Acute Lymphoblastic Leukemia Is Associated with Deep Molecular Remissions and Favorable Outcomes

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

Omission of Maintenance in Patients with High-Risk Acute Promyelocytic Leukemia (APL) in the Era of ATRA/Arsenic Consolidation

The Impact of Cumulative Dose of Cytarabine Consolidation on Outcomes in Older Patients with Acute Myeloid Leukemia

Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow

Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response

Lysyl oxidase is associated with increased thrombosis and platelet reactivity

The Role of Post- Treatment Imaging in Detection of Relapsed Disease in Classical Hodgkin Lymphoma: The Cleveland Clinic Experience

CD14 and Tissue Factor Positive Extracellular Vesicles Predict Response to Dovitinib in Patients with GBM: A Pilot Study

Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib

Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib

Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only